[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Aeterna Medical Solutions SL\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":25,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100648270","evaluation-of-the-risk-of-heart-failure-in-patients-with-chronic-kidney-disease-and-type-2-diabetes-mellitus-100648270",false,"NCT07719621","Evaluation of the Risk of Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus","Implication of Albuminuria Reduction and Other Cardiorenal Effects on The Risk of Heart Failure in Patients With CKD and T2D","Inclusion Criteria: The same characteristics of the reference population: CONFIDENCE trial (NCT05254002). In brief:\n\n* Patients with chronic kidney disease (eGFR 30-90 ml\u002Fmin\u002F1.73 m²)\n* Persistent albuminuria (UACR 100-5000 mg\u002Fg)\n* Type 2 diabetes mellitus (T2D) under stable blockade of the renin-angiotensin system (ACEi\u002FARB)\n\nExclusion Criteria: The same characteristics of the reference population: CONFIDENCE trial (NCT05254002). In brief:\n\n* Participants with type 1 diabetes (T1D).\n* Participant with hepatic insufficiency classified as Child-Pugh C.\n* Participants currently treated or who were treated with Finerenone (Kerendia©) within 8 weeks prior to the screening visit.","ALL",{"count":18,"type":19},50000,"ESTIMATED","OBSERVATIONAL","The goal of this study, performed entirely with computer programs, is to learn if using a combination of two drugs works better than using one alone, in the treatment of people with chronic kidney disease and type 2 diabetes mellitus.\n\nThe main questions it aims to answer are:\n\n* How many events of heart failure, heart failure hospitalizations, and cardiovascular death happen in each group?\n* How do serious kidney problems progress in each of the groups?\n\nResearchers will compare reference therapy (finerenone) with a combination of finerenone and empagliflozin.\n\nThere will not be human participants in this study. With the help of artificial intelligence, researchers will recreate a large population of people with chronic kidney disease and type 2 diabetes mellitus. Data on their disease, treatment, and laboratory parameters will be based on and simulated using real data from previous clinical trials conducted with real participants.",[23,24],"CKD - Chronic Kidney Disease","Diabetes Mellitus Type 2",[26,24,27,28],"Chronic Kidney Disease","finerenone","empagliflozin","NOT_YET_RECRUITING","2026-08-17",{"date":32,"type":33},"2026-08-19","ACTUAL",{"date":35,"type":19},"2026-09",{"date":37,"type":19},"2026-11",{"name":39,"class":40},"Aeterna Medical Solutions SL","OTHER",""]